News und Analysen

Investing $100 can be a good amount to get started in stocks, especially if you're using a brokerage that charges low commission fees or none at all. And over time, you can steadily grow your

Healthcare stocks, particularly pharmaceutical stocks with solid dividends, make great long-term investments.

In general, the need for healthcare products and services is stable, even during

Investors in Biogen (NASDAQ: BIIB) got some great news last week as the Food and Drug Administration (FDA) approved the company's Alzheimer's drug Leqembi. But despite the big win, the stock didn't

Did you know that if you earned an average of 7% per year, your investment would double in 10 years? That's lower than the S&P 500's long-run average of 10%. Investing in some top growth stocks

Vertex Pharmaceuticals' (NASDAQ: VRTX) stock has climbed nearly 20% so far this year, and for good reason. The biotech company completed a regulatory submission for what may become its next

UnitedHealth Group (NYSE: UNH) is the largest private health insurance company in the U.S., with more than 400,000 employees. It pulled in $324.2 billion in revenue last year, making it the largest

Amid last year's difficult market, you may not have put all of your investable money to work -- in which case, you might have cash sitting on the sidelines. This would be the perfect time to deploy

At any given time, the market may not be appropriately valuing a stock based on the fundamentals of its underlying business. This is because market participants aren't always completely rational

A good measure of a truly great business is that it outperforms the broader market over the long haul. This is because over the long term total returns tend to be more closely aligned with

Biogen (NASDAQ: BIIB) once stood out as one of the most successful biotech companies. It's portfolio of blockbuster multiple sclerosis drugs grew revenue into the billions of dollars. But as the

Some decisions are hard. Others, however, are so easy that they require much less thought.

Three Motley Fool contributors believe they've found stocks to buy that definitely fall into the latter

Pharmaceutical companies depend on the patent protection they receive for their goods, so it's never a good day when it is stripped away. That was the misfortune suffered by global pharmaceutical

Turning an initial capital of, say, $1000 into double that in half a decade amounts to a compound annual growth rate of nearly 15%. That's not easy to pull off, but it is certainly possible. The

Despite lingering economic issues, the broader stock market has recovered this year. But some companies are failing to keep up for a variety of reasons. Take AbbVie (NYSE: ABBV) and Amgen (NASDAQ:

Medical device companies don't have the flash that biotech stocks or other healthcare stocks do. Their profit margins are often tight, and they can appear boring to the average investor.

Beneath

Biotech giant Regeneron (NASDAQ: REGN) has been an outstanding performer over the past year. And although its stock is still up by 20% in the trailing-12-month period, the company's shares recently

AbbVie (NYSE: ABBV) is a leading pharmaceutical company that rewards its shareholders with a generous dividend policy. The company has a history of increasing its dividends for more than 50 years in

Shares of clinical-stage biotech company Caribou Biosciences (NASDAQ: CRBU) were up more than 58% as of 11:15 a.m. ET on Thursday after Pfizer (NYSE: PFE) made a $25 million equity investment in the

If you're looking to invest in the stock market this summer, there are many great options out there to consider. Whether you're after dividends, growth, or simply long-term stability, there are

There are many ways to determine whether a stock is cheap, but one way of doing so is determining whether there is substantial upside potential for the company. And while the market often bids up

Pfizer (NYSE: PFE), Moderna (NASDAQ: MRNA), and Novavax (NASDAQ: NVAX) were all popular stocks to own when demand for COVID vaccines was strong. But these companies are all preparing for what's

The stock market appears to be gradually recovering from the disaster that was 2022. So far this year, the S&P 500 has gained 16%. While the stock market goes through ups and downs, investing in

Regeneron Pharmaceuticals' (NASDAQ: REGN) sales growth has been lackluster in recent periods. The company is hoping that a higher-dose version of its eye medication Eylea could be a catalyst for

A new month is here. And with it comes a new opportunity to invest in spectacular dividend stocks.

Three Motley Fool contributors think they know some great candidates to buy in July. Here's why